{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:22:33Z","timestamp":1773390153644,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,25]]},"DOI":"10.7759\/cureus.74438","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T01:05:31Z","timestamp":1732583131000},"source":"Crossref","is-referenced-by-count":1,"title":["Soluble Urokinase Plasminogen Activator Receptor: A Useful Marker for Predicting Mortality in COVID-19 Patients"],"prefix":"10.7759","author":[{"given":"Tushar","family":"Sehgal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambika","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gowtham","family":"Vijayabupathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maroof","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-020-1637-5","article-title":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","volume":"63","author":"Xu X","year":"2020","unstructured":"Xu X, Chen P, Wang J, et al.. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020, 63:457-60. 10.1007\/s11427-020-1637-5","journal-title":"Sci China Life Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2467","article-title":"COVID-19 in Singapore-current experience: critical global issues that require attention and action","volume":"323","author":"Wong JE","year":"2020","unstructured":"Wong JE, Leo YS, Tan CC. COVID-19 in Singapore-current experience: critical global issues that require attention and action. JAMA. 2020, 323:1243-4. 10.1001\/jama.2020.2467","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li Q","year":"2020","unstructured":"Li Q, Guan X, Wu P, et al.. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020, 382:1199-207. 10.1056\/NEJMoa2001316","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105951","article-title":"Coronavirus disease 2019 (COVID-19): current status and future perspectives","volume":"55","author":"Li H","year":"2020","unstructured":"Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020, 55:105951. 10.1016\/j.ijantimicag.2020.105951","journal-title":"Int J Antimicrob Agents"},{"key":"ref5","unstructured":"WHO COVID-19 dashboard. (2022). Accessed. July 11, 2022: https:\/\/data.who.int\/dashboards\/covid19\/cases."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25678","article-title":"Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle","volume":"92","author":"Lu H","year":"2020","unstructured":"Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020, 92:401-2. 10.1002\/jmv.25678","journal-title":"J Med Virol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui DS","year":"2020","unstructured":"Hui DS, I Azhar E, Madani TA, et al.. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020, 91:264-6. 10.1016\/j.ijid.2020.01.009","journal-title":"Int J Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang C","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395:497-506. 10.1016\/S0140-6736(20)30183-5","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen N","year":"2020","unstructured":"Chen N, Zhou M, Dong X, et al.. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020, 395:507-13. 10.1016\/S0140-6736(20)30211-7","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5114\/ait.2020.93756","article-title":"COVID-19 - what should anaethesiologists and intensivists know about it?","volume":"52","author":"Wujtewicz M","year":"2020","unstructured":"Wujtewicz M, Dylczyk-Sommer A, Aszkie\u0142owicz A, Zdanowski S, Piwowarczyk S, Owczuk R. COVID-19 - what should anaethesiologists and intensivists know about it?. Anaesthesiol Intensive Ther. 2020, 52:34-41. 10.5114\/ait.2020.93756","journal-title":"Anaesthesiol Intensive Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou F","year":"2020","unstructured":"Zhou F, Yu T, Du R, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395:1054-62. 10.1016\/S0140-6736(20)30566-3","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.04.001","article-title":"Sepsis: current dogma and new perspectives","volume":"40","author":"Deutschman CS","year":"2014","unstructured":"Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity. 2014, 40:463-75. 10.1016\/j.immuni.2014.04.001","journal-title":"Immunity"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.7931","article-title":"Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality","volume":"18","author":"Chen D","year":"2019","unstructured":"Chen D, Wu X, Yang J, Yu L. Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality. Exp Ther Med. 2019, 18:2984-92. 10.3892\/etm.2019.7931","journal-title":"Exp Ther Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.10.011","article-title":"suPAR: the unspecific marker for disease presence, severity and prognosis","volume":"46","author":"Eugen-Olsen J","year":"2015","unstructured":"Eugen-Olsen J, Giamarellos-Bourboulis EJ. suPAR: the unspecific marker for disease presence, severity and prognosis. Int J Antimicrob Agents. 2015, 46:S33-4. 10.1016\/j.ijantimicag.2015.10.011","journal-title":"Int J Antimicrob Agents"},{"key":"ref15","unstructured":"Clinical management protocol. COVID-19. (2022). Accessed: July 11, 2022: https:\/\/covid19dashboard.mohfw.gov.in\/pdf\/ClinicalManagementProtocolforCOVID19dated27062020.pdf."},{"key":"ref16","unstructured":"Clinical guidance for management of adult covid-19 patients. (2021). Accessed. May 19, 2021: https:\/\/covid19dashboard.mohfw.gov.in\/pdf\/COVID19ClinicalManagementProtocolAlgorithmAdults19thMay2021.pdf."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.791716","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) independently predicts severity and length of hospitalisation in patients with COVID-19","volume":"8","author":"Enocsson H","year":"2021","unstructured":"Enocsson H, Idoff C, Gustafsson A, et al.. Soluble urokinase plasminogen activator receptor (suPAR) independently predicts severity and length of hospitalisation in patients with COVID-19. Front Med (Lausanne). 2021, 8:791716. 10.3389\/fmed.2021.791716","journal-title":"Front Med (Lausanne)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcle.2020.05.004","article-title":"Crucial laboratory parameters in COVID-19 diagnosis and prognosis: an updated meta-analysis","volume":"155","author":"Soraya GV","year":"2020","unstructured":"Soraya GV, Ulhaq ZS. Crucial laboratory parameters in COVID-19 diagnosis and prognosis: an updated meta-analysis. Med Clin (Engl Ed). 2020, 155:143-51. 10.1016\/j.medcle.2020.05.004","journal-title":"Med Clin (Engl Ed)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25770","article-title":"Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19","volume":"92","author":"Gao Y","year":"2020","unstructured":"Gao Y, Li T, Han M, et al.. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020, 92:791-6. 10.1002\/jmv.25770","journal-title":"J Med Virol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12873-021-00544-x","article-title":"suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department","volume":"21","author":"Santeri S","year":"2021","unstructured":"Santeri S, Peter AA, Kristiina N, Jesper EO, Harri H. suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department. BMC Emerg Med. 2021, 21:149. 10.1186\/s12873-021-00544-x","journal-title":"BMC Emerg Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2015-205444","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study","volume":"33","author":"Rasmussen LJ","year":"2016","unstructured":"Rasmussen LJ, Ladelund S, Haupt TH, et al.. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J. 2016, 33:769-75. 10.1136\/emermed-2015-205444","journal-title":"Emerg Med J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003441","article-title":"Combining national early warning score with soluble urokinase plasminogen activator receptor (suPAR) improves risk prediction in acute medical patients: a registry-based cohort study","volume":"46","author":"Rasmussen LJ","year":"2018","unstructured":"Rasmussen LJ, Ladelund S, Haupt TH, Ellekilde GE, Eugen-Olsen J, Andersen O. Combining national early warning score with soluble urokinase plasminogen activator receptor (suPAR) improves risk prediction in acute medical patients: a registry-based cohort study. Crit Care Med. 2018, 46:1961-8. 10.1097\/CCM.0000000000003441","journal-title":"Crit Care Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02897-4","article-title":"Soluble urokinase plasminogen activator receptor\u00a0(suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia","volume":"24","author":"Rovina N","year":"2020","unstructured":"Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ. Soluble urokinase plasminogen activator receptor\u00a0(suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care. 2020, 24:187. 10.1186\/s13054-020-02897-4","journal-title":"Crit Care"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03336-0","article-title":"Plasma levels of the active form of suPAR are associated with COVID-19 severity","volume":"24","author":"Huang M","year":"2020","unstructured":"Huang M, Li L, Shen J, et al.. Plasma levels of the active form of suPAR are associated with COVID-19 severity. Crit Care. 2020, 24:704. 10.1186\/s13054-020-03336-0","journal-title":"Crit Care"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/11772719211034685","article-title":"suPAR cut-offs for risk stratification in patients with symptoms of COVID-19","volume":"16","author":"Altintas I","year":"2021","unstructured":"Altintas I, Eugen-Olsen J, Sepp\u00e4l\u00e4 S, et al.. suPAR cut-offs for risk stratification in patients with symptoms of COVID-19. Biomark Insights. 2021, 16:11772719211034685. 10.1177\/11772719211034685","journal-title":"Biomark Insights"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac224","article-title":"Facilitating safe discharge through predicting disease progression in moderate coronavirus disease 2019 (COVID-19): a prospective cohort study to develop and validate a clinical prediction model in resource-limited settings","volume":"75","author":"Chandna A","year":"2022","unstructured":"Chandna A, Mahajan R, Gautam P, et al.. Facilitating safe discharge through predicting disease progression in moderate coronavirus disease 2019 (COVID-19): a prospective cohort study to develop and validate a clinical prediction model in resource-limited settings. Clin Infect Dis. 2022, 75:e368-79. 10.1093\/cid\/ciac224","journal-title":"Clin Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738093","article-title":"Plasma gradient of soluble urokinase-type plasminogen activator receptor is linked to pathogenic plasma proteome and immune transcriptome and stratifies outcomes in severe COVID-19","volume":"12","author":"Sarif J","year":"2021","unstructured":"Sarif J, Raychaudhuri D, D'Rozario R, et al.. Plasma gradient of soluble urokinase-type plasminogen activator receptor is linked to pathogenic plasma proteome and immune transcriptome and stratifies outcomes in severe COVID-19. Front Immunol. 2021, 12:738093. 10.3389\/fimmu.2021.738093","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/317882-soluble-urokinase-plasminogen-activator-receptor-a-useful-marker-for-predicting-mortality-in-covid-19-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T01:05:35Z","timestamp":1732583135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/317882-soluble-urokinase-plasminogen-activator-receptor-a-useful-marker-for-predicting-mortality-in-covid-19-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.74438","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}